Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States

International Journal of Cardiology

Volumn 181, Issue , 2015, Pages 417-424

  Chen, Christina X ^a   Hay, Joel W ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Adherence; Cost effectiveness; Familial hypercholesterolemia; Genetic testing; Statin

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; BLOOD; COST BENEFIT ANALYSIS; ECONOMICS; EPIDEMIOLOGY; FEMALE; GENETIC SCREENING; GENETICS; HUMAN; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME; UNITED STATES;

AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COST-BENEFIT ANALYSIS; FEMALE; GENETIC TESTING; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; TREATMENT OUTCOME; UNITED STATES;

EID: 84947201443     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.12.070     Document Type: Article

References (50)

1. P. Sharma, D. Boyers, C. Boachie, F. Stewart, Z. Miedzybrodzka, W. Simpson, M. Kilonzo, P. McNamee, and G. Mowatt Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation Health Technol. Assess. 16 17 2012 1 266
2. R. Alonso, J.C. Defesche, D. Tejedor, S. Castillo, M. Stef, N. Mata, P. Gomez-Enterria, C. Martinez-Faedo, L. Forga, and P. Mata Genetic diagnosis of familial hypercholesterolemia using a DNA-array based platform Clin. Biochem. 42 9 2009 899 903
3. M.A. Austin, C.M. Hutter, R.L. Zimmern, and S.E. Humphries Familial hypercholesterolemia and coronary heart disease: a HuGE association review Am. J. Epidemiol. 160 5 2004 421 429
4. P.A. Heidenreich, J.G. Trogdon, O.A. Khavjou, J. Butler, K. Dracup, M.D. Ezekowitz, E.A. Finkelstein, Y. Hong, S.C. Johnston, and A. Khera Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association Circulation 123 8 2011 933 944
5. M.H. Kong, G.C. Fonarow, E.D. Peterson, A.B. Curtis, A.F. Hernandez, G.D. Sanders, K.L. Thomas, D.L. Hayes, and S.M. Al-Khatib Systematic review of the incidence of sudden cardiac death in the United States J. Am. Coll. Cardiol. 57 7 2011 794 801
6. P.W. Sullivan, and V. Ghushchyan Preference-based EQ-5D index scores for chronic conditions in the United States Med. Decis. Making 26 4 2006 410 420
7. N.J. Stone, J. Robinson, A.H. Lichtenstein, C.N. Bairey Merz, D.M. Lloyd-Jones, C.B. Blum, P. McBride, R.H. Eckel, J.S. Schwartz, and A.C. Goldberg ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J. Am. Coll. Cardiol. 2013 2013
8. T.P. Leren, T.H. Finborud, T.E. Manshaus, L. Ose, and K.E. Berge Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening Community Genet. 11 1 2008 26 35
9. R.M. Ned, and E.J. Sijbrands Cascade screening for familial hypercholesterolemia (FH) PLoS Curr. 3 2011 (RRN1238)
10. P.J. Marang-van de Mheen, A.H. ten Asbroek, L. Bonneux, G.J. Bonsel, and N.S. Klazinga Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in the Netherlands Eur. Heart J. 23 24 2002 1922 1930
11. L. Nherera, D. Marks, R. Minhas, M. Thorogood, and S.E. Humphries Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies Heart 97 14 2011 1175 1181
12. J. Oliva, J. Lopez-Bastida, S.G. Moreno, P. Mata, and R. Alonso Cost-effectiveness analysis of a genetic screening program in the close relatives of Spanish patients with familial hypercholesterolemia Rev. Esp. Cardiol. 62 1 2009 57 65
13. D. Wonderling, M.A. Umans-Eckenhausen, D. Marks, J.C. Defesche, J.J. Kastelein, and M. Thorogood Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in the Netherlands Semin. Vasc. Med. 4 1 2004 97 104
14. R.H. Chapman, C.P. Ferrufino, S.L. Kowal, P. Classi, and C.S. Roberts The cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugs Int. J. Clin. Pract. 64 2 2010 169 181
15. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report Circulation 106 25 2002 3143 3421
16. A. Neil, J. Cooper, J. Betteridge, N. Capps, I. McDowell, P. Durrington, M. Seed, and S.E. Humphries Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study Eur. Heart J. 29 21 2008 2625 2633
17. R.A. Kronmal, K.C. Cain, Z. Ye, and G.S. Omenn Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data Arch. Intern. Med. 153 9 1993 1065 1073
18. M.R. Gold, J.E. Siegel, L.B. Russell, and M.C. Weinstein Cost-Effectiveness in Health and Medicine 1996 Oxford University Press New York
19. A.S. Go, D. Mozaffarian, V.L. Roger, E.J. Benjamin, J.D. Berry, W.B. Borden, D.M. Bravata, S. Dai, E.S. Ford, and C.S. Fox Heart disease and stroke statistics - 2013 update: a report from the American Heart Association Circulation 127 1 2013 e6 e245
20. G.J. Blake, P.M. Ridker, and K.M. Kuntz Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia Am. J. Med. 114 6 2003 485 494
21. C. Martin, M. Vanderpump, and J. French Description and validation of a Markov model of survival for individuals free of cardiovascular disease that uses Framingham risk factors BMC Med. Inform. Decis. Mak. 4 2004 6
22. Heart Protection Study Collaborative Group Statin cost-effectiveness in the United States for people at different vascular risk levels Circ. Cardiovasc. Qual. Outcomes 2 2 2009 65 72
23. J.P. Greving, E. Buskens, H. Koffijberg, and A. Algra Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk Circulation 117 22 2008 2875 2883
24. R. Grieve, J. Hutton, and C. Green Selecting methods for the prediction of future events in cost-effectiveness models: a decision-framework and example from the cardiovascular field Health Policy 64 3 2003 311 324
25. R.B. D'Agostino Sr., R.S. Vasan, M.J. Pencina, P.A. Wolf, M. Cobain, J.M. Massaro, and W.B. Kannel General cardiovascular risk profile for use in primary care: the Framingham heart study Circulation 117 6 2008 743 753
26. N.K. Kapur, and K. Musunuru Clinical efficacy and safety of statins in managing cardiovascular risk Vasc. Health Risk Manag. 4 2 2008 341 353
27. P. Jones, S. Kafonek, I. Laurora, and D. Hunninghake Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) Am. J. Cardiol. 81 5 1998 582 587
28. J.S. Benner, R.J. Glynn, H. Mogun, P.J. Neumann, M.C. Weinstein, and J. Avorn Long-term persistence in use of statin therapy in elderly patients JAMA 288 4 2002 455 461
29. H. Caspard, A.K. Chan, and A.M. Walker Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia Clin. Ther. 27 10 2005 1639 1646
30. P.H. Jones, M.H. Davidson, E.A. Stein, H.E. Bays, J.M. McKenney, E. Miller, V.A. Cain, and J.W. Blasetto Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR∗ trial) Am. J. Cardiol. 92 2 2003 152 160
31. J.K. Lee, K.A. Grace, and A.J. Taylor Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial JAMA 296 21 2006 2563 2571
32. J.R. Beck, J.P. Kassirer, and S.G. Pauker A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method Am. J. Med. 73 6 1982 883 888
33. E. Weinblatt, S. Shapiro, C.W. Frank, and R.V. Sager Prognosis of men after first myocardial infarction: mortality and first recurrence in relation to selected parameters Am. J. Public Health Nations Health 58 8 1968 1329 1347
34. W.B. Kannel, P. Sorlie, and P.M. McNamara Prognosis after initial myocardial infarction: the Framingham study Am. J. Cardiol. 44 1 1979 53 59
35. R.L. Sacco, P.A. Wolf, W.B. Kannel, and P.M. McNamara Survival and recurrence following stroke. The Framingham study Stroke 13 3 1982 290 295
36. M.S. Dennis, J.P. Burn, P.A. Sandercock, J.M. Bamford, D.T. Wade, and C.P. Warlow Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project Stroke 24 6 1993 796 800
37. G.W. Torrance Measurement of health state utilities for economic appraisal J. Health Econ. 5 1 1986 1 30
38. P. Dolan Modeling valuations for EuroQol health states Med. Care 35 11 1997 1095 1108
39. M.B. Clearfield, J. Amerena, J.P. Bassand, H.R. Hernandez Garcia, S.S. Miller, F.F. Sosef, M.K. Palmer, and B.S. Bryzinski Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia - Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR) Trials 7 2006 35
40. D.G. Fryback, E.J. Dasbach, R. Klein, B.E. Klein, N. Dorn, K. Peterson, and P.A. Martin The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors Med. Decis. Making 13 2 1993 89 102
41. C.I. Coleman, A.D. Straznitskas, D.M. Sobieraj, J. Kluger, and M.W. Anglade Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable Am. J. Cardiol. 109 7 2012 1020 1025
42. J. Hanmer, W.F. Lawrence, J.P. Anderson, R.M. Kaplan, and D.G. Fryback Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores Med. Decis. Making 26 4 2006 391 400
43. 2013 CPT Codes and Client Price List http://www.ambrygen.com/sites/default/files/Price-List-By-Name-06-27-2013.pdf (accessed June 2013)
44. Physician Fee Schedule Search http://www.cms.gov/apps/physician-fee-schedule/search/search-results.aspx?Y=0&T=0&HT=0&CT=0&H1=99214&M=1 (accessed June 2013)
45. D.M. Huse, M.W. Russell, J.D. Miller, D.F. Kraemer, R.B. D'Agostino, R.C. Ellison, and S.C. Hartz Cost-effectiveness of statins Am. J. Cardiol. 82 11 1998 1357 1363
46. M. Pignone, S. Earnshaw, J.A. Tice, and M.J. Pletcher Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis Ann. Intern. Med. 144 5 2006 326 336
47. M.W. Russell, D.M. Huse, S. Drowns, E.C. Hamel, and S.C. Hartz Direct medical costs of coronary artery disease in the United States Am. J. Cardiol. 81 9 1998 1110 1115
48. L. Goldman, M.C. Weinstein, P.A. Goldman, and L.W. Williams Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease JAMA 265 9 1991 1145 1151
49. Macroeconomics and Health: Investing in Health for Economic Development Health CoMa 2001 World Health Organization Geneva
50. H.A. Glick, J.A. Doshi, S.S. Sonnad, and D. Polsky Economic Evaluation in Clinical Trials 2007 Oxford University Press New York, NY